Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.

Ji S, Kim HS, Kim JW, Jee MK, Park KW, Uh Y, Lee DK, Song JS, Baik SK, Kwon SO.

J Gastroenterol Hepatol. 2006 Sep;21(9):1381-7.

PMID:
16911680
2.

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.

PMID:
12121503
3.
4.

A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.

Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T.

Dig Dis Sci. 2005 Sep;50(9):1625-31.

PMID:
16133961
5.

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.

Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T.

J Gastroenterol Hepatol. 2001 Jul;16(7):723-8.

PMID:
11446878
6.

Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T.

Dig Dis Sci. 2008 Apr;53(4):933-7. Epub 2007 Oct 13.

PMID:
17934830
7.
8.
10.

Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.

Ariizumi K, Ohara S, Koike T, Inomata Y, Iijima K, Sekine H, Noguchi M, Sugiyama K, Eda Y, Kayaba S, Kawamura M, Shimosegawa T.

J Gastroenterol Hepatol. 2006 Sep;21(9):1428-34. Erratum in: J Gastroenterol Hepatol. 2006 Dec;21(12):1871.

PMID:
16911688
11.
12.

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.

Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.

PMID:
14696516
13.

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.

Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M.

Eur J Gastroenterol Hepatol. 2003 Jan;15(1):27-33.

PMID:
12544691
14.

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.

Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M.

Aliment Pharmacol Ther. 2001 Sep;15(9):1479-84.

15.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
16.

CYP2C19 genotype and the PPIs--focus on rabeprazole.

Lim PW, Goh KL, Wong BC.

J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S22-8. Review.

PMID:
16359346
17.

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.

Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.

Aliment Pharmacol Ther. 1999 Feb;13(2):179-86.

18.

Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.

Wada F, Murase K, Isomoto H, Soda H, Takeshima F, Omagari K, Mizuta Y, Tsukamoto K, Murata I, Kohno S.

J Int Med Res. 2002 Jul-Aug;30(4):413-21.

PMID:
12235924
19.

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.

Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E.

Ann Intern Med. 1998 Dec 15;129(12):1027-30.

PMID:
9867757
20.

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.

Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.

Aliment Pharmacol Ther. 2000 Oct;14(10):1259-66.

Supplemental Content

Support Center